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18F-FDG: 18F-Fluorodeoxyglucose  
CI: confidence interval 
CRP: C-reactive protein 
CT: computed tomography 
ESR: erythrocyte sedimentation rate 
GCA: giant cell arteritis 
IQR: interquartile range 
LVV: large-vessel vasculitis 
OR: odds ratio 
PMR: polymyalgia rheumatica 
PET/CT: positron emission tomography/computed tomography 
















Objective:  Polymyalgia rheumatica (PMR) is often the presenting manifestation of 
giant cell arteritis (GCA). Fluorine-18-fluorodeoxyglucose positron emission 
tomography/computed tomography (PET/CT) scan often discloses the presence of 
large vessel vasculitis (LVV) in PMR patients. We aimed to identify predictive factors of 
a positive PET/CT scan for LVV in patients classified as having isolated PMR according 
to well-established criteria.  
Methods: A set of consecutive patients with PMR from a single hospital were 
assessed. All of them underwent PET/CT scan between January 2010 and February 
2018 based on clinical considerations. Patients with PMR associated to other diseases, 
including those with cranial features of GCA, were excluded. The remaining patients 
were categorized in classic PMR (if fulfilled the 2012 EULAR/ACR classification criteria 
at disease diagnosis; n=84) or atypical PMR (who did not fulfill these criteria; n=16). 
Only information on patients with classic PMR was assessed. 
Results: The mean age of the 84 patients (51 women) with classic PMR was 71.4±9.2 
years. A PET/CT scan was positive in 51(60.7%). Persistence of classic PMR 
symptoms was the most common reason to perform a PET/CT scan. Nevertheless, 
patients with positive PET/CT scan often had unusual symptoms. The best set of 
predictors of a positive PET/CT scan were bilateral diffuse lower limb pain (OR=8.8, 
95% CI 1.7-46.3; p=0.01), pelvic girdle pain (OR=4.9, 95% CI 1.50-16.53; p=0.01) and 
inflammatory low back pain (OR=4.7, 95% CI 1.03-21.5; p=0.04). 
Conclusion: Inflammatory low back pain, pelvic girdle and diffuse lower limb pain are 
predictors of positive PET/CT scan for LVV in PMR. 
 
Key words: polymyalgia rheumatica, giant cell arteritis, large vessel vasculitis, PET/CT 
scan, predictors. 




Polymyalgia rheumatica (PMR) is a relatively common disease among 
individuals of European background [1,2]. It occurs mainly in people older than 50 
years [1,2]. Pain and stiffness involving the shoulder girdle and the proximal aspects of 
the arms are typical features of this condition [3]. Other common manifestations are 
pain and stiffness in the neck, pelvic girdle and thighs [3]. In most cases, PMR is 
associated with elevation of acute phase proteins, erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP) [3]. 
Although PMR symptoms may be observed in a large spectrum of conditions 
that sometimes mimic a “pure” PMR [4], the most remarkable association of PMR is 
with giant cell arteritis (GCA) [5]. As occurs with PMR, GCA is also more common in 
people older than 50 years of European descent, in particular those with Scandinavian 
background [1,2].  
PMR and GCA are often overlapping conditions, and PMR may be the 
presenting manifestation of GCA [5]. Although in a population based-study almost 50% 
of patients with classic biopsy-proven GCA had PMR manifestations [6], most studies 
indicate that the frequency of patients with PMR who have concomitant GCA is 
approximately 20% [7,8]. 
The classic pattern of GCA is characterized by the presence of cranial ischemic 
manifestations. Nevertheless, some patients with GCA present large-vessel vasculitis 
(LVV) features without headache, abnormal temporal arteries on physical examination 
or other typical manifestations of this entity [9]. In these cases, the temporal artery yield 
is lower than in the classic cranial form of GCA [9]. With respect to this, the advent of 
new imaging techniques has allowed us to identify a large proportion of GCA patients 
who have LVV involvement without cranial ischemic manifestations. This is especially 
true when we use fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission 
tomography/computed tomography (PET/CT) [10].  
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Despite a major advance in the diagnosis of GCA, an issue that remains a 
challenge for the clinicians who treat PMR is to identify those individuals who have a 
“silent” underlying LVV. Interestingly, a positive 18F-FDG PET/CT scan showing the 
presence of LVV is observed in at least a third of the patients presenting with PMR [3]. 
Although PMR and GCA exhibit a rapid response to corticosteroids in most cases, the 
initial dose required for the management of these conditions is certainly different. Thus, 
whereas 12.5-25 mg/day of prednisone/prednisolone is the initial dose of glucocorticoid 
recommended by the EULAR expert Committee for the management of PMR [11], this 
dose is in most cases insufficient to prevent severe ischemic manifestations in patients 
with GCA [12,13]. Moreover, in some cases, patients initially diagnosed as having 
isolated PMR experience a relapse that include features of a previously silent GCA 
[13]. In this regard, Narvaez et al. retrospectively reviewed a series of 167 patients with 
GCA. Seventy-nine percent of them were diagnosed with GCA by a positive temporal 
artery biopsy and the remaining by well-established classification criteria. Eighteen 
(11%) of these 167 patients were initially diagnosed with isolated PMR. At that time, 
they did not have clinical manifestations of GCA and all of them showed a rapid 
response to 10-20 mg/day of prednisone, with normalization of the acute-phase 
proteins. However, during the follow-up, 17 patients had relapses with cranial ischemic 
manifestations of GCA and 1 patient suffered an upper extremity vascular insufficiency 
due to stenotic involvement of the left subclavian and axillary arteries. Moreover, 9 of 
these 18 patients initially diagnosed as having isolated PMR suffered severe ischemic 
complications of GCA, including visual ischemic complications in 7, with permanent 
visual loss in 2 of them [13]. These observations highlight the need for a close-follow-
up of patients diagnosed as having “pure” isolated PMR. In this regard, an issue of 
major relevance is to identify those patients with PMR who have LVV involvement in 
the setting of GCA. Although 18F-FDG PET/CT scan is useful to demonstrate the 
presence of LVV in patients presenting with PMR, this technique is expensive and 
associated with radiation exposure.   
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Taking all these considerations into account, in the present study, we aimed to 
identify predictive factors of a positive 18F-FDG PET/CT scan for LVV in patients 
presenting with well-defined PMR without cranial manifestations of GCA.  
 
2. PATIENTS AND METHODS 
Patients 
A set of consecutive patients were prospectively included in the study. They 
were diagnosed with PMR at a single tertiary care center. All of them underwent 18F-
FDG PET/CT scan between January 2010 and February 2018, based on clinical 
considerations, to identify the presence of LVV involvement. 
 
Inclusion and exclusion criteria and clinical definitions 
During the recruitment period, patients with polymyalgia symptoms associated 
with cranial ischemic manifestations suggestive of GCA, such as headache, abnormal 
temporal artery on physical examination, jaw claudication, scalp tenderness or visual 
ischemic manifestations were excluded. In this regard, none of the patients included in 
the present study fulfilled the 1990 American College of Rheumatology classification 
criteria for GCA [14]. Patients with PMR symptoms associated with another underlying 
inflammatory or neoplastic disease that could mimic PMR were also excluded [3,4].   
The remaining patients were categorized into classic PMR (if fulfilled the 2012 
EULAR/ACR classification criteria at disease diagnosis) or atypical PMR (patients with 
PMR symptoms who did not fulfill these criteria) [15].  Most patients (n= 84) were 
classified as having classic (typical) PMR. At the time of disease diagnosis, these 
patients were older than 50 years old, had predominant inflammatory shoulder pain 
and elevation of acute phase proteins (ESR and/or CRP). All of them tested negative 
for rheumatoid factor and anti-cycle citrullinated peptide antibodies and did not exhibit 
peripheral arthritis. Based on the attending physician’s decision, a temporal artery 
biopsy of at least 1 cm in length was performed in 36 of them. In all cases the histology 
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was informed as normal (negative for GCA). A few patients (n= 16) had polymyalgia 
manifestations but they did not fulfill the 2012 EULAR/ACR classification criteria. Six of 
them were under 50 years of age at the time of PMR diagnosis (range of age in these 6 
patients: 43-48 years). Another 10 patients did not complain of relevant pain and 
stiffness in the arms and shoulder girdle at any time. However, they had typical 
inflammatory pain involving the pelvic girdle and the proximal aspects of the limbs. In 
addition, these 16 patients had elevation of acute phase proteins (ESR and/or CRP). 
No other conditions were found to be responsible for the polymyalgia syndrome in 
these 16 patients after at least one year of follow-up since the onset of polymyalgia 
symptoms. Moreover, none of them developed cranial ischemic manifestations over the 
extended follow-up period.  
The reasons for requesting a PET/CT scan in patients with classic PMR were 
the following: 1) Persistence of typical classic PMR features despite receiving a 
treatment with at least 15 mg/day of prednisone. 2) Occurrence of unusual 
manifestations, such as inflammatory low back pain or bilateral diffuse lower limb pain 
(including in some cases intermittent claudication pain on movement in the lower 
extremities). 3) Development of marked constitutional symptoms (with or without fever) 
in the follow-up period despite receiving glucocorticoid therapy. 4) Unexplained 
increase of acute phase proteins (ESR and/or CRP) despite therapy.  
In PMR patients who did not fulfill the 2012 EULAR/ACR classification criteria, a 
PET/CT scan was requested because of the unusual presentation of symptoms or if 
PMR patients were under 50 years of age.  
Epidemiological differences between patients with classic and atypical PMR are 
shown in Table 1. Patients with atypical PMR were younger and had a shorter duration 
of symptoms when a 18F-FDG PET/CT scan was requested than those with classic 
PMR. Although the percentage of positive PET/CT scan was greater in the atypical 
forms of PMR, the difference did not reach statistical significance, possibly due to the 
small number of patients with atypical PMR (n=16). In addition, in an attempt to identify 
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the presence of LVV in patients with well-defined PMR, only patients with classic 
presentation at the time of disease diagnosis, who at that time were included in the 
category of classic PMR were included in the analysis. 
 
Definitions of atypical manifestations 
Inflammatory low back pain was considered to be present if the patient 
presented low back pain that improved with movement but not with rest, and it was 
usually predominant at night. Bilateral diffuse lower limb pain was defined when the 
patient complained of pain in both legs, in the thighs as well as anywhere between the 
knees and the ankles. Patients with these symptoms often complained of muscle pain 
on mild exertion such as walking, predominantly in the calves, which improved by a 
short period of rest [16]. Constitutional symptoms were considered to be present if the 
patient had asthenia, anorexia and/or weight loss greater than 5% of the normal body 
weight during the last six months. Fever was defined if the temperature was ≥ 38ºC 
without any evidence of infectious or neoplastic underlying disease. 
 
Laboratory data 
All patients with classic PMR had initially been treated with prednisone at an 
initial dose of least 15 mg/day. They were still taking prednisone (mean± standard 
deviation [SD]: 12.1±6.3 mg/day) when the 18F-FDG PET/CT scan was performed. 
CRP was considered to be abnormal at the time of performing 18F-FDG PET/CT scan if 
the value was higher than 0.5 mg/dL. At that time, an ESR level above 20 mm/1st hour 
was also considered elevated.  
 
PET/CT scan equipment and protocol 
Patients had to be in a low carbohydrate diet 48 hours before the scan, with 
reduced physical exercise for 24 hours and fasting state for at least 6 hours before 18F-
FDG administration. Serum glucose level was lower than 160 mg/dL in all the patients. 
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Whole-body PET/CT scan was acquired 180 minutes after intravenous injection of 7 
MBq/kg of 18F-FDG using a Biograph LSO Pico 3D (Siemens Healthcare Molecular 
Imaging, Hoffman Estates, Illinois, USA). A low dose CT scan for attenuation correction 
and anatomic localization was first obtained, followed by a PET scan (acquiring 250 
s/bed position). Images were reconstructed using the ordered subsets-expectation 
maximization (OSEM) algorithm (2 iterations, 8 subsets). Images were visually 
evaluated by two experienced nuclear medicine specialists according to the intensity of 
the 18F-FDG uptake by the vessel wall at the supraaortic trunks, thoracic aorta, 
abdominal aorta, iliac arteries and femoral/tibioperoneal arteries. PET/CT images were 
visually evaluated grading the vascular FDG uptake in comparison to liver uptake. 
PET/CT scans were considered positive for active LVV when a pattern of linear uptake 
was found in the aorta wall and its branches (when involved) with an intensity similar or 
higher than the liver, according to previous reports [17-19] and the recently published 
recommendations of the European Association of Nuclear Medicine, The Society of 
Nuclear Medicine and Molecular Imaging, and the PET Interest Group, and endorsed 
by the American Society of Nuclear Cardiology [20]. Figures 1A and 1B shows two 
representative cases of PMR with negative and positive PET/CT scan for LVV, 
respectively. 
The diagnosis of LVV was established by the combination of clinical data, 
treatment response, and initial and follow-up PET/CT scan. 




All continuous variables were tested for normality, and results were expressed 
as mean ±SD or as median and interquartile range (IQR) as appropriate. Student's t 
test or Mann-Whitney U-test were used to compare continuous variables, and Chi-
square-test for categorical variables. Multivariable stepwise logistic regression 
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analyses were conducted to identify the independent set of predictors for a positive 18F-
FDG PET/CT scan. The predicted probability for a positive imaging result was 
calculated from the regression model for each patient. The reliability of the model was 
evaluated using the Hosmer-Lemeshow goodness-of-fit test. The area under the ROC 
curve and its 95% confidence interval (CI) tested the discriminative ability of the 
regression model. A p value <0.05 was considered as statistically significant in all the 
calculations. Data management and analysis were performed using SPSS Statistics for 
Windows, version 18.0 (SPSS Inc., Chicago, Ill., USA) [21].  
 
3. RESULTS 
The mean age of the 84 patients (51 women/33 men) with classic PMR was 
71.4±9.2 years. A PET/CT scan was positive in 51(60.7%) of them. 
Persistence of classic PMR symptoms, alone or associated to the presence of 
unusual manifestations and/or constitutional symptoms, was the most common reason 
for requesting a PET/CT scan (Table 2). 
 
Differences between patients with classic PMR according to PET/CT scan results 
The main clinical and laboratory differences between patients with classic PMR 
who had a positive 18F-FDG PET/CT scan for LVV and those in whom this procedure 
was negative are shown in Table 2. No differences in the age and sex between those 
with positive and negative 18F-FDG PET/CT scan were observed. It was also the case 
for the presence of classic cardiovascular risk factors. With regard to the typical PMR 
features, patients with positive 18F-FDG PET/CT scans had more commonly pelvic 
girdle involvement than those with negative 18F-FDG PET/CT scans (86.3% versus 
36.4%; p<0.01). More importantly, patients with classic PMR who had a positive 18F-
FDG PET/CT scan showed more commonly atypical PMR features, such as 
inflammatory low back pain (29.4% versus 9.1%; p= 0.027) or diffuse lower limb pain 
(52.9% versus 6.1%; p<0.01) at the time of PET/CT scan performance (Figures 2A 
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and 2B). However, no differences between patients with positive and negative 18F-FDG 
PET/CT scan were observed according to the presence of constitutional symptoms 
(including fever in this category). Also, the values of laboratory markers of inflammation 
and the dose of prednisone at the time of 18F-FDG PET/CT scan were similar in both 
groups (Table 2). 
 
Multivariate logistic regression model showing the best set of predictors for the 
presence of LVV in the PET/CT scan  
Table 3 shows the best set of predictors of a positive 18F-FDG PET/CT-scan for 
LVV. They were bilateral diffuse lower limb pain (odds ratio-OR=8.8, 95% CI 1.7-46.3; 
p=0.01), pelvic girdle pain (OR=4.9, 95% CI 1.50-16.53; p=0.01) and inflammatory low 
back pain (OR=4.7, 95% CI 1.03-21.5; p=0.04) once adjusted for age and sex. Further 
adjustments, including for diabetes status, did not virtually change these results.  
Figure 3 shows the ROC analysis of the full predictive model for a positive 18F-
FDG PET/CT scan result showing LVV in patients with classic PMR (area under the 
curve 0.85 [95% CI 0.76- 0.93]; p<0.0001). A cut-off point of 0.55 yielded a sensitivity 
of 86% and a specificity of 64%. The correspondent figures for a cut-off point of 0.70 
were 65% and 91%.  
 
4. DISCUSSION 
The present study confirms that patients who fulfill well-established 
classification criteria for PMR often have LVV. Interestingly, besides the classic pelvic 
girdle involvement, the presence of atypical symptoms, such as inflammatory low back 
pain or bilateral diffuse pain in the lower extremities, was a predictor of underlying LVV 
in these patients at the time of PET/CT scan evaluation.   
Experts in the field consider that PET/CT scans may show LVV involvement in 
at least a third of patients with PMR [22-24]. The results of our study suggest that the 
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prevalence of LVV in patients with well-defined PMR may be higher, reaching in our 
series up to 60%. Our results were in keeping with a former prospective study of our 
group that included 40 consecutive patients (27 women/13 men, 68.10±10.27 years) 
with PMR assessed by 18F-FDG PET/CT scan.  In that study, this imaging technique 
disclosed LVV in 26 of the 40 patients [25]. The high percentage of LVV in our PMR 
series can be explained in part by the criteria used for the interpretation of PET/CT 
scan images. As Lavado-Pérez et al. did, we used a more delayed acquisition protocol 
in comparison to that applied in oncological patients, because it has demonstrated a 
better visualization of the vessel wall uptake, due to the decrease of the blood pool 
activity and the increase in the lesion/background ratio [18,19].  
Early detection of LVV in patients with PMR is of potential relevance to 
determine the actual spectrum of the disease [26-28]. 18F-FDG PET/CT has 
demonstrated to be very sensitive to make an early diagnosis of LVV [29-36]. However, 
information aimed to identify clinical and laboratory predictors of a positive 18F-FDG 
PET/CT for LVV in patients with PMR is scarce [37]. In this sense, in a multicenter 
retrospective study that included patients with GCA, PMR and other inflammatory 
disorders assessed by 18F-FDG PET/CT scan, Hooisma et al. reported that an elevated 
ESR was a positive predictor whereas arthralgia was a negative predictor for LVV [37]. 
Nevertheless, they concluded that a reliable prediction of the result of the 18F-FDG 
PET/CT based only on these two parameters was not possible [37]. In the present 
study we assessed patients with well-defined PMR, including for this purpose only 
those who fulfilled 2012 EULAR/ACR classification criteria [15]. According to our 
results, besides pelvic girdle pain, atypical manifestations, such as inflammatory low 
back pain and lower diffuse limb pain, were predictors of a positive 18F-FDG PET/CT 
scan result for LVV in patients with PMR. Noteworthy, 18F-FDG PET/CT was negative 
for LVV in all our patients when it was performed because of a marked unexplained 
elevation of serum CRP and ESR levels not associated to typical or atypical 
manifestations of the disease. Thus, it seems that a reliable prediction of a positive 
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result for LVV in 18F-FDG PET/CT, based only on an elevation of acute phase proteins 
is not possible.  
A potential limitation of our study may be that our patients were taking 
prednisone at the time of PET/CT scan assessment. In this regard, glucocorticoids 
decrease the intensity of vessel wall 18F-FDG uptake [19,38,39]. However, Cimmino et 
al. [40], demonstrated that 18F-FDG PET/CT scan is useful for the evaluation of LVV in 
patients with PMR despite a previous treatment with low-dose glucocorticoids. This is 
especially true if PET/CT scan is performed within the first 3 days after the onset of 
glucocorticoid therapy [20]. 
As occurs in the majority of studies of this type, another limitation was the absence of 
histological confirmation of LVV. Moreover, the size of the study group could also be 
considered as a potential limitation. However, we think that our series of patients with 
classic PMR was large enough to disclose predictors of LVV in PMR patients 
undergoing 18F-FDG PET/CT scan. Moreover, to the best of our knowledge, the 
present study constitutes the first attempt to identify the best set of predictors for LVV 
in a series of patients classified as having PMR according to the 2012 EULAR/ACR 
classification criteria. In addition, the presence of a positive PET/CT scan in our 
patients with persistent PMR manifestations was clinically useful and led us to increase 




In conclusion, our findings indicate that in patients with classic PMR, besides 
pelvic girdle pain, the presence of inflammatory low back pain and diffuse lower limb 
pain may have clinical relevance to identify a LVV by 18F-FDG PET/CT scan. In 
agreement with experts in the field [28], we feel that higher physician awareness and 
broader use of vascular imaging techniques to disclose LVV involvement is needed in 
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FIGURE LEGENDS 
 Figure 1A.   An 88-year-old man with PMR. Although the patient experienced a 
rapid response to prednisone (15 mg/day), he suffered an unexplained increase 
of ESR/CRP not associated with polymyalgia symptoms. Because of that, a 
PET/CT-scan was performed to exclude LVV. Coronal (A), sagittal (B) and axial 
(C) 
18
F-FDG PET images ruled out inflammation of large vessels. 
 Figure 1B.  A 69-year-old woman with PMR and persistence of classic PMR 
symptoms despite prednisone therapy along with unusual symptoms 
(inflammatory low back pain) at the time of assessment. Sagittal PET (A) and 
fused PET/CT (B), axial PET (C) and fused PET/CT (D), and coronal PET (E) 
images (E) showed inflammation along the thoracic aorta wall (head arrows) 
and supra-aortic trunks (arrows).  
 Figure 2. A 63-year-old woman, who initially had with typical PMR features, 
started to complain of diffuse lower limb pain and intermittent vascular 
claudication associated to persistent pelvic girdle pain when prednisone dose 
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was tapered. Besides typical bursitis in the setting of PMR demonstrated by 18F-
FDG PET/CT in the shoulders and cervical and lumbar interspinous spaces, 
trochanteric and ischiatic regions of both hips (arrows) (Figure 2A), the images 
also disclosed the presence of LVV with increased 18F-FDG uptake involving 
the femoral arteries (Figure 2B). A mild 18F-FDG uptake was also observed at 
the thoracic aortic wall (Figure 2A). 
 Figure 3. ROC analyzing the performance of the full predictive model of a 
positive 18F-FDG PET/CT scan result for LVV in patients with classic PMR. 




Table 1. Epidemiological differences between classic and atypical PMR. 
 
Table 2. Main clinical features and laboratory findings of 84 patients with classic PMR 
when the PET/CT scan was performed.  
  







Age (years), mean ±SD 69.34 ± 10.6 71.4 ± 9.2 58.4 ± 10.9 < 0.01 
Sex (women), n (%) 61 (61.0) 51 (60.7) 10 (62.5) 0.89 
Duration of symptoms* 
(mo), median [IQR] 
12.0 [6.0-40.0] 14.0 [6.0-40.0] 6.0 [3.5-11.5] 0.004 
Positive PET/CT scan 
result, n (%) 
63 (63.0) 51 (60.7) 12 (75.0) 0.29 
PET/CT: positron emission tomography complemented by computed tomography; PMR: 
polymyalgia rheumatica; IQR: interquartile range; SD: standard deviation. * At the time of 




Classic PMR (N=84) 





Sex (women), n (%) 31 (62.7) 19 (57.6) 0.64 
Age (years), mean ±SD 70.0 ± 9.2 73.7 ± 9.0 0.09 
Cardiovascular risk factors, n (%)   
Hypertension 29 (56.9) 24 (72.7) 0.14 
Dyslipidemia 18 (35.3) 16 (48.5) 0.23 
Diabetes mellitus 10 (19.6) 12 (36.4) 0.09 
Current smokers 5 (9.8) 1 (3.0) 0.40 
Polymyalgia symptoms, n (%)    
Neck pain 9 (17.6) 9 (27.3) 0.29 
Shoulder girdle pain 33 (64.7) 26 (78.8) 0.17 
Pelvic girdle pain 44 (86.3) 12 (36.4) < 0.01 
Morning stiffness 11 (21.6) 10 (30.3) 0.44 
Unusual symptoms, n (%)    
Inflammatory low back pain 15 (29.4) 3 (9.1) 0.027 
Diffuse lower limb pain 27 (52.9) 2 (6.1) < 0.01 
Constitutional symptoms, n (%)    
Fever 2 (3.9) 2 (6,1) 0.64 
Asthenia 15 (29.4) 8 (24.2) 0.60 
Hyporexia 4 (7.8) 7 (21.2) 0.08 
Weight loss 9 (17.6) 8 (24.2) 0.46 
Laboratory markers,    
Hb (g/dL), mean ± SD 12.7 ± 1.3 12.2 ± 1.6 0.09 
Platelet count (×10
9
/l), mean ± SD 281.4 ± 84.9 263.7 ± 100.3 0.19 
CRP (mg/dL),  median [IQR] 2.0 [0.6-4.4] 2.0 [1.1-5.3] 0.28 
ESR (mm/1
st




Treatment,     
Glucocorticoids, n (%) 51 (100.0) 33 (100.0) 0.99 
Dose of Prednisone (mg), mean ± SD 12.0 ± 5.7 12.3 ± 7.3 0.88 
Months of treatment with Prednisone, median [IQR] 4 [1.0-15.0] 7 [2.5-15.5] 0.31 
Methotrexate, n (%) 11 (21.6) 4 (12.1) 0.27 
 
Reasons for PET/CT scan request, n (%) 
   
Persistence of classic PMR symptoms* 8 (15.7) 10 (30.3) 0.19 
Presence of unusual symptoms without classic PMR 
symptoms* 
1 (2.0)  1 (3.0) 0.69 
Presence of constitutional symptoms without classic PMR or 
unusual symptoms* 
1 (2.0) 2 (6.1) 0.69 
Unexplained increase of ESR/CRP not associated with 
classic PMR symptoms or unusual symptoms 
0 (0.0) 4 (12.1) 0.04 
Persistence of classic PMR symptoms + unusual 
symptoms* 
25 (49.0) 5 (15.2) 0.003 
Persistence of classic PMR symptoms + constitutional 
symptoms* 
4 (7.8) 9 (27.3) 0.04 
Persistence of classic PMR symptoms + constitutional 
symptoms + unusual symptoms* 
12 (23.5) 2 (6.1) 
0.07 
 
CRP: serum C reactive protein; ESR: erythrocyte sedimentation rate; Hb: hemoglobin; PET/CT: positron emission tomography 
complemented by computed tomography; PMR: polymyalgia rheumatica; IQR: interquartile range; SD: standard deviation.   
*In most cases associated with mild or moderate elevation of ESR and/or CRP. 
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Table 3. Multivariate logistic regression model showing the best set of predictors of a 
positive result for LVV in 18F-FDG PET/CT scan in patients with classic PMR. 
Variable Beta OR 95% CI P 
Classic PMR 
Diffuse low back pain 1.55 4.7 1.03-21.5 0.04 
Lower limb pain 2.17 8.8 1.70-46.3 0.01 
Pelvic girdle pain 1.58 4.9 1.50-16.3 0.01 
CI: confidence interval; OR: odds ratio; PMR: polymyalgia rheumatica. 
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